Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.

Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View

AbbVie

Amgen

Biogen

Bristol-Myers

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Novartis

Pfizer

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

Intuitive Surgical

Profitable. Great revenue and earnings growth.

My Top Healthcare Stocks to Buy in the Market Crash

With the coronavirus pandemic growing rapidly, the company doesn't see drug studies as the best use of healthcare resources right now.

Vertex Pharmaceuticals to Pause Some Clinical Trials

ABIOMED

Arista Networks

Alphabet

Incyte

IPG Photonics

Regeneron Pharmaceuticals

Skyworks Solutions

Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather the current downturn.

10 Stocks To Buy With Low Debt And High Liquidity

Moderna

Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.

4 Reasons Biotech Stocks Are a Buy Right Now

Trade Desk

Stuck at home because of the COVID-19 outbreak? Make money over the long run by investing in these great stocks.

3 Stocks to Buy to Make Your Coronavirus Lockdown a Profitable One

Vertex is the IBD Stock Of The Day as VRTX stock parries coronavirus worries on enthusiasm for its new cystic fibrosis treatment. Vertex stock is weathering well in the correction.

IBD Stock Of The Day: Why Coronavirus Isn't Slamming This Biotech Leader

Exelixis

These biotechs' profits shouldn't be dented by the COVID-19 pandemic. And their growth prospects appear to be really good.

Coronavirus Crisis: 3 Biotech Stocks to Buy Right Now

Vertex Confirms 20% Revenue Growth Forecast, Presents A Compelling Investment Opportunity

GW Pharmaceuticals

A rebounding stock market lifted all three of these biotech stocks.

Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped Today

Eli Lilly

Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.

4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy

Co-Diagnostics

We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.

4 Top Biotech Stocks to Buy in the Time of Coronavirus

DexCom

Masimo

In the coronavirus bear market, all stocks are under quarantine. But keep health care stocks Vertex, Biogen, Dexcom, Eli Lilly, Masimo under observation.

Coronavirus Bear Market: All Stocks Are Under Quarantine, But Keep Vertex, Biogen, Dexcom, Eli Lilly, Masimo Under Observation

The recent drop in the share prices of biotech and related health care companies could present traders with a buying opportunity.

3 Charts Suggest Traders Will Remain Bullish on Biotech

Three steps you can take to follow Warren Buffett's advice and achieve extraordinary long-term results.

How to Be Greedy When Others Are Fearful

Global Blood Therapeutics

Despite fears of a COVID-19 pandemic, these two stocks are worth considering.

2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market

BioMarin Pharmaceutical

Blueprint Medicines

Galapagos

Ligand Pharmaceuticals

The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.

5 Biotech Stocks to Buy for a Strong Growth Prognosis

These stocks aren't likely to be infected with the current market worries.

3 Biotech Stocks That Are Coronavirus Safe Havens

Evo Payments

Fortinet

HealthEquity

Mitek Systems

These top-ranked stocks are likely to beat on the bottom line in their next release.

5 Top Stocks With Great Earnings Beat Potential

Teladoc

Looking for great stocks to buy if the market rebounds in a big way? Think healthcare.

3 Top Healthcare Stocks to Buy in March

Apple

Disney

You'll might want to consider the same approach.

All the Stocks I'm Selling If the Coronavirus Keeps Spreading

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?

Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Vertex (VRTX) Is a Great Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

News for Vertex Pharmaceuticals Stock (VRTX)